Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
Abstract Toll-like receptors (TLRs) are a potential target for cancer immunotherapy due to their role in the activation of the innate immune system. More specifically, TLR7 and TLR8, two structurally similar pattern recognition receptors that trigger interferon and cytokine responses, have proven to...
Main Authors: | Varshney, Dhruv (Author), Qiu, Sherry Yue (Author), Graf, Tyler P. (Author), McHugh, Kevin J. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC,
2022-02-09T16:44:29Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
by: Varshney, Dhruv, et al.
Published: (2021) -
Development of a novel TLR8 agonist for cancer immunotherapy
by: Yuxun Wang, et al.
Published: (2020-09-01) -
Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
by: Yuxun Wang, et al.
Published: (2021-05-01) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
by: Giorgio Frega, et al.
Published: (2020-01-01) -
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
by: Stefanie R. Mullins, et al.
Published: (2019-09-01)